drugset / Trial / NCT00249119

A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia

NCT00249119

Phase 3 Completed 1579 enrolled Janssen, LP
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate the effectiveness and safety of different doses of risperidone (an antipsychotic medication) compared with a fixed 10-mg dose of a standard antipsychotic, haloperidol, in patients with chronic schizophrenia.

Timeline

Start
Primary completion
Completion
1991-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 0.5 mg Oral
Subject Risperidone Other / unclassified 2 mg Oral
Subject Risperidone Other / unclassified 4 mg Oral
Subject Risperidone Other / unclassified 6 mg Oral
Subject Risperidone Other / unclassified 8 mg Oral

Indications